Anagliptin

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Anagliptin
Anagliptin.svg
Clinical data
Trade names Suiny
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • Approved in Japan
Identifiers
CAS Number
ChemSpider
Chemical and physical data
Formula C19H25N7O2
Molar mass 383.45 g/mol
3D model (Jmol)

Anagliptin (INN; trade name Suiny) is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It is approved for use in Japan.[1] It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins".[2]

References[edit]

  1. ^ A.I. Graul; B. Lupone; E. Cruces; M. Stringer (2013). "2012 in Review - Part I: The Year's New Drugs and Biologics" (PDF). Drugs of Today. 49 (1): 33–68. doi:10.1358/dot.2013.49.1.1933991. 
  2. ^ Kato, Noriyasu; Oka, Mitsuru; Murase, Takayo; Yoshida, Masahiro; Sakairi, Masao; Yamashita, Satoko; Yasuda, Yoshika; Yoshikawa, Aya; Hayashi, Yuuji; Makino, Mitsuhiro; Takeda, Motohiro; Mirensha, Yakufu; Kakigami, Takuji (2011). "Discovery and pharmacological characterization of N-\2-({2-\(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo\1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor". Bioorganic & Medicinal Chemistry. 19 (23): 7221. doi:10.1016/j.bmc.2011.09.043.